Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2013

Open Access 01-12-2013 | Research

Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies

Authors: Albert W Wu, Kristin A Hanson, Gale Harding, Seema Haider, Margaret Tawadrous, Alexandra Khachatryan, Chris L Pashos, Kit N Simpson

Published in: Health and Quality of Life Outcomes | Issue 1/2013

Login to get access

Abstract

Background

Selection of an appropriate patient-reported outcome (PRO) instrument for a clinical trial requires knowledge of the instrument’s responsiveness to detecting treatment effects. The purpose of this study was to examine the responsiveness of two health-related quality of life (HRQL) instruments used in clinical trials involving HIV-infected adults: the HIV-targeted Medical Outcomes Study HIV Health Survey (MOS-HIV), and a generic measure, the EuroQol-5D (EQ-5D).

Methods

A systematic review identified clinical trials using the MOS-HIV or EQ-5D to assess outcomes for HIV-infected adults. Data abstracted from each study included study type, treatment regimen(s), PRO results, and effect size (either reported or calculated). Effect size was calculated as the difference between baseline and follow-up mean scores divided by the baseline standard deviation. Magnitude was categorized as small (d=0.20), medium (d=0.50), and large (d=0.80).

Results

Between 2005 and 2010, the MOS-HIV was administered in 12 trials. Significant differences were observed between groups and over time in physical health summary (PHS) and mental health summary (MHS) scores (P<0.05) in subjects switching therapy after experiencing Grade-2 adverse events. Effect sizes were medium (0.55 and 0.49 for PHS and MHS, respectively) among treatment-naïve adults beginning therapy (two studies), but negligible among treatment-experienced adults (0.04 and 0.13 for PHS and MHS, respectively; three studies). The EQ-5D was used in five trials between 2001 and 2010. It was responsive to occurrences of adverse events and opportunistic infections, with small-to-medium effect sizes (range 0.30–0.50) in each of its five dimensions.

Conclusions

A systematic review of PRO study results showed both the MOS-HIV and EQ-5D were responsive to changes between groups and/or over time in treatment-naïve HIV-infected patients. These instruments may be used either individually or together in clinical trials to measure changes in HRQL.
Appendix
Available only for authorised users
Literature
1.
Food and Drug Administration: Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2009, 74: 65132–65133.
2.
Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ: A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics 2006, 24: 751–765. 10.2165/00019053-200624080-00003PubMedCrossRef
3.
4.
Wu AW, Jacobson KL, Frick KD, Clark R, Revicki DA, Freedberg KA, Scott-Lennox J, Feinberg J: Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res 2002, 11: 273–282. 10.1023/A:1015240103565PubMedCrossRef
5.
6.
Wu AW, Hays RD, Kelly S, Malitz F, Bozzette SA: Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res 1997, 6: 531–554. 10.1023/A:1018460132567PubMedCrossRef
7.
Wu AW: MOS-HIV Health Survey Users Manual. Baltimore, Maryland: Johns Hopkins University; 1999.
8.
Wu AW, Revicki DA, Jacobson D, Malitz FE: Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997, 6: 481–493. 10.1023/A:1018451930750PubMedCrossRef
9.
Revicki DA, Sorensen S, Wu AW: Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care 1998, 36: 126–137. 10.1097/00005650-199802000-00003PubMedCrossRef
10.
Rabin R, Oemar M, Oppe M: EQ-5D-3L User Guide: Basic information on how to use the EQ-5D-3L instrument. Version 4.0. Rotterdam, The Netherlands: EuroQol Group; 2011.
11.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011, 20: 1727–1736. 10.1007/s11136-011-9903-xPubMedCentralPubMedCrossRef
12.
Chang BH, Boehmer U, Zhao Y, Sommers E: The combined effect of relaxation response and acupuncture on quality of life in patients with HIV: a pilot study. J Altern Complement Med 2007, 13: 807–815. 10.1089/acm.2007.7024PubMedCentralPubMedCrossRef
13.
Bucciardini R, Fragola V, Massella M, Polizzi C, Mirra M, Goodall R, Carey D, Hudson F, Zajdenverg R, Floridia M, Initio Trial International Coordinating C: Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy. AIDS Res Hum Retroviruses 2007, 23: 1215–1222. 10.1089/aid.2007.0067PubMedCrossRef
14.
Huang IC, Wu AW, Finnern HW, Thijs H, Gathe JC, Fairclough DL: Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens. Antivir Ther 2008, 13: 15–25.PubMed
15.
Lafaurie M, Collin F, Bentata M, Garre M, Leport C, Levy Y, Goujard C, Chene G, Molina JM, Group AS: Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial. J Antimicrob Chemother 2008, 62: 1122–1129. 10.1093/jac/dkn309PubMedCrossRef
16.
Sprinz E, Neto AJ, Bargman E, Green SL, Luo MP, Sylte JR, McMillan FI, King KR, Rode RA, Brun SC: Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy. HIV Clin Trials 2006, 7: 291–308. 10.1310/hct0706-291PubMedCrossRef
17.
Nuesch R, Gayet-Ageron A, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Chautrakarn S, Ruxrungtham K: The impact of combination antiretroviral therapy and its interruption on anxiety, stress, depression and quality of life in Thai patients. Open AIDS J 2009, 3: 38–45. 10.2174/1874613600903010038PubMedCentralPubMedCrossRef
18.
Powers AE, Marden SF, McConnell R, Leidy NK, Campbell CM, Soeken KL, Barker C, Davey RT, Dybul MR: Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection. AIDS 2006, 20: 837–845. 10.1097/01.aids.0000218547.39339.13PubMedCrossRef
19.
Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC: Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr 2009, 51: 631–639. 10.1097/QAI.0b013e3181a4f00dPubMedCrossRef
20.
Wu AW, Snyder CF, Huang IC, Skolasky R, McGruder HF, Celano SA, Selnes OA, Andrade AS: A randomized trial of the impact of a programmable medication reminder device on quality of life in patients with AIDS. AIDS Patient Care STDS 2006, 20: 773–781. 10.1089/apc.2006.20.773PubMedCrossRef
21.
Shalit P, True A, Thommes JA, Investigators Q: Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study. HIV Clin Trials 2007, 8: 24–35. 10.1310/hct0801-24PubMedCrossRef
22.
Levine AM, Salvato P, Leitz GJ, Champs 2 Study G: Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients. AIDS Res Hum Retroviruses 2008, 24: 131–139. 10.1089/aid.2006.0200PubMedCrossRef
23.
Stangl AL, Wamai N, Mermin J, Awor AC, Bunnell RE: Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda. AIDS Care 2007, 19: 626–636. 10.1080/09540120701203915PubMedCrossRef
24.
Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA, Group PS: HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001, 15: 1811–1822. 10.1097/00002030-200109280-00010PubMedCrossRef
25.
Bucciardini R, Massella M, Corpolongo A, Narciso P, Fragola V, Mirra M, Donnini S, Vigano O, Costarelli S, Tozzi V: T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy. Biologics 2008, 2: 577–581.PubMedCentralPubMed
26.
Bhargava A, Booysen Fle R: Healthcare infrastructure and emotional support are predictors of CD4 cell counts and quality of life indices of patients on antiretroviral treatment in Free State Province, South Africa. AIDS Care 2010, 22: 1–9.PubMedCrossRef
Metadata
Title
Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies
Authors
Albert W Wu
Kristin A Hanson
Gale Harding
Seema Haider
Margaret Tawadrous
Alexandra Khachatryan
Chris L Pashos
Kit N Simpson
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2013
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-11-42

Other articles of this Issue 1/2013

Health and Quality of Life Outcomes 1/2013 Go to the issue

Research

Patient-reported outcomes in adequately treated hypothyroidism – insights from the German versions of ThyDQoL, ThySRQ and ThyTSQ

Research

Association between sense of coherence and health-related quality of life among primary care patients with chronic musculoskeletal pain

Research

Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to disability change: a longitudinal study

Research

Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients

Research

Factors associated with health-related quality of life in renal transplant recipients: results of a national survey in France

Research

Development and evaluation of a crosswalk between the SF-36 physical functioning scale and Health Assessment Questionnaire disability index in rheumatoid arthritis